09:21 AM EDT, 10/15/2025 (MT Newswires) -- Novo Nordisk ( NVO ) and Omeros ( OMER ) said Wednesday that they have signed an asset purchase and license deal, under which Novo Nordisk ( NVO ) will get exclusive global rights to develop and commercialize Omeros' ( OMER ) drug candidate zaltenibart in all indications.

In a filing with the US Securities and Exchange Commission, Omeros ( OMER ) said it is eligible to receive up to $2.1 billion in payments linked to potential development and commercial milestones, including an upfront payment at closing, as well as tiered royalties on net sales.

The transaction is expected to close in Q4, after which Novo Nordisk ( NVO ) intends to start a global phase 3 study of zaltenibart in rare blood disorder paroxysmal nocturnal hemoglobinuria, the parties said.

Zaltenibart, an antibody designed to inhibit the protein MASP-3, is under clinical development for rare blood and kidney disorders, the companies said.

Novo Nordisk's ( NVO ) stock was 0.8% lower in recent Wednesday premarket activity, while Omeros' ( OMER ) stock was up more than 185%.